by Jakub Jarolím, Business Intelligence Department
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
SOTIO Biotech
24/7/2023
June 2023 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions
Market
The Inflation Reduction Act may lead to an increase in partnering and acquisition activity
Biotech companies with long-dated cash flows are impacted by macroeconomic uncertainty, inflation, and interest rates. While the Inflation Reduction Act is widely considered a negative for innovative drug development, it may also lead to an increase in corporate alliances and acquisition activity.
Interleukin-15 and Interleukin-2
Alkermes presented two posters related to its nemvaleukin during ASCO
Alkermes published new posters at ASCO related to nemvaleukin alfa, the novel, investigational, engineered interleukin-2 variant immunotherapy. Trial-in-progress posters from the actively recruiting phase 2 ARTISTRY-6 clinical trial and phase 3 ARTISTRY-7 clinical trial were presented.
Antibody-Drug Conjugates
Elahere to become standard of care in ovarian cancer
ImmunoGen presented full data from Phase 3 trial evaluating Elahere mirvetuximab soravtansine-gynx, which has accelerated approval to treat FOLR1-positive ovarian cancer.
Cell Therapies
Gracell gains on recent positive FastCAR data in B cell NHL
Shares of Gracell Biotechnologies have nearly doubled following a pair of positive readouts from the company’s lead program, a FastCAR T cell therapy targeting both CD19 and BCMA to treat B cell non-Hodgkin’s lymphoma and multiple myeloma.
Other Innovative Treatment Areas
GSK’s PD-1 gets priority review in first-line endometrial cancer
GSK is looking forward to a PDUFA date of Sept. 23 after FDA granted priority review to an sBLA for Jemperli dostarlimab plus chemotherapy as first-line therapy for dMMR/MSI-H advanced or recurrent endometrial cancer, an indication where no other PD-1 inhibitors have been approved.
Sdílet na sociálních sítích